|Day's Range||6.550 - 6.565|
|52 Week Range||5.010 - 9.060|
|PE Ratio (TTM)||1.46|
|Earnings Date||Jun 7, 2017 - Jun 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||42.67|
SANTA MONICA, Calif., March 27, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced the completion ...
During the quarter, the company signed an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones are met. Once SWK receives back 1.5 times their investment, Opiant will receive at least 90% of future NARCAN® royalties and milestone payments. Total revenue for the fiscal second quarter was $13.535 million, compared to $6.86 million during the three months ending Jan. 31, 2016.
Categories: Yahoo Finance Get free summary analysis Opiant Pharmaceuticals, Inc. reports financial results for the quarter ended January 31, 2017. We analyze the earnings along side the following peers of Opiant Pharmaceuticals, Inc. – GW Pharmaceuticals PLC Sponsored ADR and Arena Pharmaceuticals, Inc. (GWPH-US and ARNA-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)